A murine study from 2018 showed that IL-6 treatment enhances AKT signaling and reduces gluconeogenic gene expression in livers from low and high fat fed mice, demonstrating that the beneficial effects of IL-6 on glucose and insulin homeostasis, in vivo, are maintained in obesity (178). This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.